cancer

Early detection and appropriate treatment essential for prostate cancer

Early detection and appropriate treatment essential for prostate cancer

Leave a Comment / Genetics / By

According to estimates by the American Cancer Society, there will be 268,490 new cases of prostate cancer in 2022, along with 34,500 deaths from prostate cancer.1 These are staggering numbers that show just how common the disease is among American men. While these numbers are concerning, there is a silver lining: the 15-year relative survival …

Early detection and appropriate treatment essential for prostate cancer Read More »

Genes & Cancer | Ectopic expression of MHIV lncRNA as a potential diagnostic biomarker in cervical cancer

Genes & Cancer | Ectopic expression of MHIV lncRNA as a potential diagnostic biomarker in cervical cancer

Leave a Comment / Genetics / By

image: Figure 1: MHIV lncRNA expression in CC tumor compared to non-tumor marginal tissues. see After Credit: 2022 Ghanbari et al. BUFFALO, NY – December 9, 2022 – A new research article has been published in Genes and Cancer on November 23, 2022, entitled “Ectopic expression of MHIV lncRNA as a potential diagnostic biomarker in …

Genes & Cancer | Ectopic expression of MHIV lncRNA as a potential diagnostic biomarker in cervical cancer Read More »

Genetic test could help some breast cancer patients avoid radiation after lumpectomy

Genetic test could help some breast cancer patients avoid radiation after lumpectomy

Leave a Comment / Genetics / By

By Denise Mann Health Day Reporter (Health Day) FRIDAY, Dec. 9, 2022 (HealthDay News) — A new genetic test could help determine which people with breast cancer can safely skip radiation after breast-conserving surgery to remove their tumor. People with invasive breast cancer who had low scores on an experimental gene panel were just as …

Genetic test could help some breast cancer patients avoid radiation after lumpectomy Read More »

Genetic test could help some breast cancer patients avoid radiation after lumpectomy

Genetic test could help some breast cancer patients avoid radiation after lumpectomy

Leave a Comment / Genetics / By

FRIDAY, Dec. 9, 2022 (HealthDay News) — A new genetic test could help determine which people with breast cancer can safely skip radiation after breast-conserving surgery to remove their tumor. People with invasive breast cancer who had low scores on an experimental gene panel were just as likely to experience a recurrence whether or not …

Genetic test could help some breast cancer patients avoid radiation after lumpectomy Read More »

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model

Leave a Comment / Genetics / By

Myriad Genetics, Inc. Myriad’s MyRisk™ hereditary cancer test with RiskScore® provides personalized breast cancer risk assessment for women of all backgrounds SALT LAKE CITY, 08 Dec. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a …

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model Read More »

Livestock Improvement: How Forward Pack and Sexed Semen Can Boost Genetic Gain | MarketScreener

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model | MarketScreener

Leave a Comment / Genetics / By

Myriad’s MyRisk™ hereditary cancer test with RiskScore® provides personalized breast cancer risk assessment for women of all backgrounds SALT LAKE CITY, 08 Dec. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more …

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model | MarketScreener Read More »

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model

Leave a Comment / Genetics / By

SALT LAKE CITY, 08 Dec. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a simple standard of care risk assessment. The data was shared …

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model Read More »

Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors

Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors

Leave a Comment / Genetics / By

NEW YORK – For patients whose HER2-negative and hormone receptor-positive metastatic breast cancers progress after treatment with combination CDK4/6 inhibitors and hormone therapy, there is no additional benefit to continuing treatment with Pfizer Ibrance’s CDK4/6 inhibitor (palbociclib) plus another hormone therapy as the next line of treatment, suggest phase II study results presented at the …

Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors Read More »

When genetic mutations cause chromosomes to break apart and fuse together in different ways, normal cells can become cancerous. In this image, normal chromosomes (blue) are shown with chromosomes (green and red) that have been altered using CRISPR-Cas9 genome engineering and fused back together.<br><br> <a href="https://www.salk.edu/wp-content/uploads/2022/11/Dixon-lab-image.jpg">Click here</a> for a high-resolution image.<br><br> Credit: Salk Institute

Flipping the switch: Salk scientists shed new light on genetic changes that turn cancer genes on – Salk Institute for Biological Studies

Leave a Comment / Genetics / By

December 7, 2022 Flipping the switch: Salk scientists shed new light on genetic changes that turn cancer genes on New research into cancer-causing gene mutations could lead to better ways to predict and treat disease December 7, 2022 LA JOLLA—Cancer, caused by an abnormal proliferation of cells, is the second leading cause of death worldwide. …

Flipping the switch: Salk scientists shed new light on genetic changes that turn cancer genes on – Salk Institute for Biological Studies Read More »

Race may affect breast cancer outcomes in women with similar genetic recurrence scores

Leave a Comment / Genetics / By

06 December 2022 3 minute read Source/Disclosures Published by: Source: Abdou Y, et al. Abbreviated GS1-01. Presented at: San Antonio Breast Cancer Symposium; December 10, 6-10, 2022; Saint Anthony. Disclosures: NIH, NCI, Susan G. Komen for the Cure Research Program, Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Genomic Health (now Exact Sciences …

Race may affect breast cancer outcomes in women with similar genetic recurrence scores Read More »